Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer opens London peptide center; Xencor wins $105M from Alexion.
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial
On 4th try, Outlook scores FDA nod for reformulated version of Roche's Avastin for AMD
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
Lilly, Resilience commit $750M to boost US diabetes, obesity med production
